Nicotinamide Adenine Dinucleotide Market Size, Share, Industry, Forecast and outlook 2024-2031

Nicotinamide Adenine Dinucleotide Market is segmented By Grade (Food Grade, Pharmaceutical Grade, Others), By Application (Dietary Supplements, Pharmaceuticals, Others), and By Region (North America, South America, Europe, Asia Pacific) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Nicotinamide Adenine Dinucleotide Market Overview

Nicotinamide Adenine Dinucleotide Market is forecasted to reach at a CAGR of 11.25 % during the forecast period (2024-2031)

The pyridine nucleotide nicotinamide adenine dinucleotide (NAD+) is a critical cofactor and substrate for several essential cellular processes, including DNA repair, epigenetically modulated gene expression, intracellular calcium signaling, and immunological functions. As suggested by its name, it comprises two nucleotides, one with an adenine base and the other with a nicotinamide base. Their shared phosphate groups bind them together. NAD generally comes in two forms: oxidized and reduced, denoted by NAD+ and NADH abbreviations. NAD can also be used as a critical supplemental anti-aging medication. One of the most well-known NAD supplements in contemporary biological research is NADH, a mitochondrial hormone that lengthens cells' life cycles (anti-aging). NAD+ is also primarily used in catabolic pathways, such as glycolysis, which breaks down energy molecules to create ATP. All living cells use the coenzyme nicotinamide adenine dinucleotide for their respiratory processes (NAD).

Nicotinamide Adenine Dinucleotide Market Summary

For More Insights Request Free Sample

Nicotinamide Adenine Dinucleotide Market Dynamics

Increasing consumers health awareness towards NAD drives market expansion

The market's growth is fueled by the use of NAD, making it easier to sleep and eat at the proper times. Additionally, the rise in disposable income among people around the world has brought about lifestyle changes. This has increased the popularity of fast food. As a result, increased consumption of junk food has brought an imbalance in the body's cholesterol levels. This will probably increase the demand for medications and fuel the growth of the Nicotinamide Adenine Dinucleotide (NAD) market. NAD can also be produced from nicotinic acid or tryptophan. On the other hand, NAD can be used to treat most cancers. Therefore, the demand for nicotinamide adenine dinucleotide (NAD) will rise as the prevalence of cardiovascular diseases increases globally, fueling the growth of the nicotinamide adenine dinucleotide (NAD) market.

However, government dosage regulations intended to prevent adverse health effects are predicted to limit industry growth.

Nicotinamide Adenine Dinucleotide Market Segmentation Analysis

Food grade segment accounted for the highest share in global nicotinamide adenine dinucleotide market

The highest revenue share was taken by the food grade category, and it is anticipated that it will hold that position for the anticipated amount of time. Because of NAD's antioxidant properties, its use in the food and beverage industry has grown significantly, which has raised the demand for NAD of the food grade. It is anticipated that NAD's significant role as a substrate and cofactor for numerous vital biological processes, including DNA repair and epigenetically controlled gene expression, will further drive the market.

On the other hand, over the forecast period, the pharmaceuticals category is expected to expand significantly. The popularity of NAD as an active ingredient in the production of numerous health medications has increased demand for NAD among pharmaceutical companies. There is anticipated to be a sizable demand for NAD in the pharmaceutical industry due to the efficiency of NAD-boosting medications in repairing DNA damage and modifications to prevent diseases like Alzheimer's disease, dementia, and Parkinson's disease.

Nicotinamide Adenine Dinucleotide Market Geographical Share

Asia Pacific is the dominating region during the forecast period

Asia Pacific region may emerge as a major hub for this industry owing to the wide applicability of NAD in manufacturing nutrition and supplementation together with its growing adoption in the pharma sector. Additionally, increasing demand for improving immunization to chronic diseases, along with the strong presence of market players, is estimated to stimulate regional market growth. North America is expected to hold a significant market revenue share in the year 2021. Growing awareness related to the health benefits among the consumer is the key factor that helps in boosting the market growth in the region. In addition, a growing number of cardiovascular diseases in the region will create a demand for the NAD.

Nicotinamide Adenine Dinucleotide Market Companies and Competitive Landscape

There are several established participants in the industry and local manufacturers; hence, the market is fragmented. The nicotinamide adenine dinucleotide industry is expected to see several product innovation initiatives, strategic partnerships, mergers, and acquisitions by industry participants. Some of the key players in the industry are Bontac Bioengineering, Hefei Home Sunshine Pharmaceutical Technology Co., Ltd., F. Hoffmann-La Roche Ltd, HiMedia Laboratories, NutriScience Innovations, LLC, Nutrifoods, Bontac Bio-engineering(shenzhen)co., ltd, Krackeler Scientific, Shandong Lankang Bio-Technology Co., Ltd, and Shenzhen Hygieia Biotechnology Co., Ltd. For instance, On December 7, 2021, Biocon Limited, an innovation-led global biopharmaceutical company, partnered with Tabuk Pharmaceutical Manufacturing Company, a leading pharmaceutical company in the Middle East and North Africa (MENA), to commercialize select specialty products in the Middle East. The products' marketing authorization will be held by Tabuk Pharmaceuticals, which will also be in charge of their registration, importation, and promotion in Saudi Arabia and other Middle Eastern nations.

On the other hand, on 29 December 2021, Novo Nordisk acquired Dicerna Pharmaceuticals. With the completion of the merger, Dicerna became a wholly-owned subsidiary of Novo Nordisk. The common stock of Dicerna will not be disclosed on listed or traded on the Nasdaq Global Select Market.

COVID-19 Impact on Nicotinamide Adenine Dinucleotide Market

Positive impact on the global nicotinamide adenine dinucleotide market

The COVID-19 pandemic prompted business owners to protect and maintain their supply chains to meet the growing demand for their products. However, improvements in NAD supplements and products, along with growing knowledge of the benefits of the products, supported product deployment in the cosmetics and pharmaceutical sectors. In order to stay ahead of the competition and drive overall business growth, key market players in the nicotinamide adenine dinucleotide market spend a lot of time expanding their product portfolios and conducting extensive R&D projects. The outcomes of a clinical investigation on the security and tolerability of the NAD+ precursor nicotinamide riboside was released in October 2022 by the dietary supplement expert ChromaDex (NR). The results showed that NR could increase NAD+ levels, making it an innovative treatment for heart failure with a lower ejection fraction.

The global nicotinamide adenine dinucleotide market report would provide an access to approximately 53 market data tables, 43 figures and 96 pages